Rituximab is an anti-CD20 monoclonal antibody that has efficacy in B-cell non-Hodgkin's lymphoma (NHL). Adjuvant immunotherapy with rituximab may reduce relapse rates for high-risk B-cell NHL following highdose chemotherapy with autologous stem cell transplantation (SCT). However, the potential adverse effects of rituximab on immune reconstitution following SCT are not fully characterized. We performed a retrospective analysis of immunoglobulin (Ig) levels and peripheral blood neutrophil counts in 11 patients who received adjuvant rituximab following autologous SCT for B-cell NHL. Results were compared to a contemporaneous group of 24 patients who received an identical conditioning regimen and autologous SCT for lymphoma, but no adjuvant rituximab. Adjuvant rituximab was associated with a significantly increased incidence of hypogammaglobulinaemia between 12 and 24 months post-SCT, but not neutropenia. Despite suppression of Igs, there were no late or atypical infective complications attributable to rituximab.
Introduction
High-dose chemotherapy with autologous stem cell transplantation (SCT) provides one of the most effective treatments for high-risk B-cell lymphomas.
1 Despite this intensive therapy, relapse rates for patients with chemorefractory and/or relapsed disease remain unsatisfactory. Post transplant adjuvant immunotherapy with rituximab may reduce relapse rates by eliminating minimal residual disease (MRD) and removing malignant cells re-infused with the autograft. 2, 3 Although rituximab has been reported to be well tolerated post-SCT, 3 it has been associated with delayed episodes of neutropenia. 4, 5 Rituximab-induced neutropenia was linked to profound hypogammaglobulinaemia in most cases. A prospective study of adjuvant rituximab and immune reconstitution following autologous SCT reported a 60% incidence of delayed neutropenia, with suppression of immunoglobulin (Ig) levels in a third of patients at 1 year. 5 Others have reported a possible increase in atypical infections such as cytomegalovirus (CMV) disease and progressive multifocal leucoencephalopathy associated with adjuvant rituximab. 6 In this study, we analysed peripheral blood counts and Ig levels at regular intervals after autologous SCT. A cohort of patients who received a course of adjuvant rituximab was compared to controls who received identical conditioning but no adjuvant therapy.
Patients and methods
All patients treated at our institution with autologous SCT and adjuvant rituximab for B-cell non-Hodgkin's lymphoma (NHL) between 1999 and 2005 were included. Patients were selected for adjuvant therapy on the basis of preliminary data supporting improved outcomes with post-SCT rituximab in follicular NHL. Several other patients with non-follicular B-cell NHL considered to be at a high risk of relapse owing to aggressive underlying disease (e.g. mantle cell NHL) were also included. A group of patients treated during the same time period for lymphoma with autologous SCT (but no adjuvant rituximab) and with a minimum follow-up of 12 months were used as comparators. Patients in both groups were considered to have high-risk disease on the basis of relapse following initial therapy or a chemorefractory disease state.
Conditioning for SCT consisted of LACE: lomustine 200 mg/m 2 on day À7, etoposide 1000 mg/m 2 day À7, cytarabine 2 g/m 2 twice daily from day À6 to day À5, and cyclophosphamide 1.8 g/m 2 daily from day À4 to day À1. Autologous peripheral blood stem cells were administered on day 0. Patients did not receive antibacterial or antifungal primary prophylaxis; however, valaciclovir was administered during the neutropenic period. Granulocyte colony-stimulating factor was not routinely administered, but given to facilitate engraftment in cases of febrile neutropenia.
Adjuvant rituximab was administered following haematopoietic recovery at 2 months following SCT. A total of four weekly doses of 375 mg/m 2 were infused according to product guidelines.
Following SCT, all patients were assessed by a standard protocol at regular intervals with clinical examination, complete blood counts, biochemical profiles, computed tomography scanning and bone marrow biopsies. The intensity of post-SCT monitoring occurred independently of rituximab administration and was therefore similar for all patients. There was no routine monitoring for CMV reactivation. Quantitative Ig levels were measured every 3 months. Hypogammaglobulinaemic patients did not receive prophylactic Ig therapy.
For statistical analysis, P-values were calculated using either a Student's t-test or a two-sided Fisher's exact test at the a ¼ 0.05 level of significance.
Results
Eleven patients with B-cell NHL who received autologous SCT followed by adjuvant rituximab were included. Twenty-four patients treated with autologous SCT but no adjuvant rituximab were evaluated as a control group. Patient and disease characteristics are summarized in Table 1 . There was no difference in age, gender and number of prior cycles of chemotherapy or stem cell dose between the adjuvant rituximab and control groups. There was a higher frequency of prior rituximab treatment in the adjuvant rituximab group. Although the mean baseline Ig level was lower in the adjuvant rituximab group, the incidence of hypogammaglobulinaemia (IgGo7.6 g/l) was similar to controls.
There was no transplant-related mortality in either of the study groups. Ten of the 11 patients in the adjuvant rituximab group were in complete remission (CR) at their first post-SCT assessment. At a median follow-up of 18 months, nine were alive and seven remain in CR. Both deaths were due to progressive lymphoma. None of the patients who received adjuvant rituximab experienced any late or atypical infective sequelae.
Twenty-two of the 24 patients in the control group were in CR at their first post-SCT assessment. At a median follow-up of 47 months, 19 were alive and all of the survivors were in remission. All deaths were due to progressive lymphoma.
Between 12 and 24 months after autologous SCT there were more hypogammaglobulinaemic patients in the adjuvant rituximab group. Results are illustrated in Figure 1 . The incidence of suppressed IgA (IgAo0.9 g/l) was higher in the adjuvant rituximab group at baseline and between 12 and 24 months (Figure 1c) , and for IgM (IgMo0.5 g/l) at 12 months only (Figure 1b ). All three of the patients who received adjuvant rituximab with followup at 2 years were hypogammaglobulinaemic. One patient who has now had 5 years of follow-up remains in CR but has persisting hypogammaglobulinaemia.
The incidence of neutropenia (neutrophil count o1.9 Â 10 9 /l) and lymphopenia (lymphocyte count o0.9 Â 10 9 /l) was similar at all time points between the adjuvant rituximab and control groups. Results are illustrated in Figure 2 .
Discussion
Rituximab is an anti-CD20 human-mouse chimeric monoclonal antibody that has activity against both aggressive and indolent B-cell NHL. The humanized Fc component mediates host effector mechanisms such as complement activation and antibody-dependent cell cytotoxicity. 7 In addition, crosslinking of CD20 on target cells promotes apoptosis, 8 thus sensitizing to and synergizing with the effects of chemotherapy. This is evidenced by improved responses when rituximab is used with lymphoma chemotherapy regimens. 9, 10 Rituximab's novel mode of action conveys a side effect profile that differs from chemotherapy. This makes it an attractive synergistic therapy to improve outcomes in SCT with little additional myelotoxicity. Post-SCT rituximab has a theoretical advantage as monoclonal antibody therapy may be more effective in MRD states. 3 Rituximab is well tolerated when incorporated into chemotherapy regimens in the non-transplant setting. Although normal B-lymphocytes are eliminated from the peripheral blood for up to 6 months following rituximab use, 11 this does not usually result in suppression of serum Ig or infective complications. However, the manipulation of normal B-lymphocytes by rituximab during immune reconstitution following SCT may exaggerate the adverse effects of rituximab on humoral immunity. Other investigators have reported an association between adjuvant rituximab and suppression of Ig for at least 12 months post-SCT. 4, 5 In our study, we analysed Ig levels from 11 patients who received adjuvant rituximab following autologous SCT for B-cell NHL. Ig levels were compared to those from a control group who were treated with autologous SCT following identical conditioning, but without adjuvant rituximab. We noted statistically significant suppression of Ig by rituximab for between 12 and 24 months following autologous SCT.
A higher incidence of pre-SCT rituximab exposure in the adjuvant group may explain the lower baseline mean Ig when compared to controls. However, the baseline incidence of hypogammaglobulinaemia was similar for both groups and remained comparable for the first 6 months post-SCT. It is therefore more likely that the later development of hypogammaglobulinaemia was related to adjuvant rituximab use rather than antecedent factors or an interaction between prior rituximab exposure and SCT.
Previous studies have linked rituximab associated hypogammaglobulinaemia to delayed neutropenia. 4, 5 We did not demonstrate a higher incidence of neutropenia in the adjuvant rituximab group at defined time points post-SCT. Our cohort of patients differs from previously reported series in that all received LACE conditioning for SCT. This conditioning regimen may be protective against later rituximab induced neutropenia when compared to BEAM or total body irradiation based protocols. Also, our patients only received one course of adjuvant therapy, where other investigators have administered additional rituximab at 6 months post-SCT. 5 It is plausible that more intense post-SCT rituximab exposure elevates the risk of delayed neutropenia. Another possibility is that late episodes of neutropenia occurred in our adjuvant rituximab group, but that these were missed on retrospective analysis of a relatively small number of patients. However, if significant complications of delayed neutropenia occurred, we would have noted the clinical consequence.
Rituximab appears to be well tolerated as adjuvant immunotherapy following autologous SCT. Our results suggest that post-SCT adjuvant rituximab may cause prolonged hypogammaglobulinaemia following autologous SCT. Despite this we did not detect any associated neutropenia or late infective complications. Figure 2 Incidence of (a) neutropenia (neutrophil count o1.9 Â 10 9 /l) and (b) lymphopenia (lymphocyte count o0.9 Â 10 9 /l) according to time post-autologous SCT. The number above each set of bars denotes number of patients evaluable at each time point. ', results for patients receiving adjuvant rituximab. , results for patients who did not receive adjuvant rituximab (P-values nonsignificant at all time points).
